A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis

Czech version

Authors: Vladimír Soška ^1,2; David Karásek ³; Vladimír Bláha ⁴; Renata Cífková ⁵; Tomáš Freiberger ⁶; Pavel Kraml ⁷; Jan Piťha ^8,9; Hana Rosolová ¹⁰; Tomáš Štulc ¹¹; Zuzana Urbanová ¹²; Michal Vrablík ¹¹
Authors‘ workplace: Oddělení klinické biochemie FN U sv. Anny v Brně ¹; II. interní klinika LF MU a FN U sv. Anny v Brně ²; III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc ³; III. interní gerontometabolická klinika LF UK a FN Hradec Králové ⁴; Centrum kardiovaskulární prevence 1. LF UK a Thomayerovy nemocnice, Praha ⁵; Centrum kardiovaskulární a transplantační chirurgie, Brno ⁶; II. interní klinika 3. LF a FN Královské Vinohrady, Praha ⁷; Interní klinika 2. LF UK a FN Motol, Praha ⁸; Laboratoř pro výzkum aterosklerózy IKEM, Praha ⁹; II. interní klinika LF UK a FN Plzeň ¹⁰; III. interní klinika 1. LF UK a VFN v Praze ¹¹; Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze ¹²
Published in: Vnitř Lék 2018; 64(12): 1124-1128
Category: Guidelines

Overview

This article summarised opinion of the European Society for Atherosclerosis on the causal relationship between low density lipoprotein (LDL) and the development of atherosclerosis. The fact that there is a clear causal relationship between the LDL concentration and the development of atherosclerotic cardiovascular disease (ASKVO) is evidenced by congenital lipid metabolism disorders and results of prospective epidemiological studies, Mendelian randomized trials, and randomized controlled trials. It is documented that the effect of LDL exposure on ASKVO development is cumulative; the additive effect of other risk factors is also discussed. In conclusion the facts, underlying the rational approach to the therapy of patients with dyslipidemia, are summarized.

Key words:

atherosclerotic cardiovascular disease – LDL – low density lipoprotein – EAS

Sources

Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459–2472. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx144>.
Di Angelantonio E, Sarwar N et al. [Emerging Risk Factors Collaboration]. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993–2000. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.1619>.
Lewington S, Whitlock G, Clarke R et al. [Prospective Studies Collaboration]. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829–1839. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(07)61778–4>. Erratum in Lancet 2008; 372(9635): 292.
Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis. J Am Coll Cardiol 2012; 60(25): 2631–2639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.09.017>.
Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.
Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207–274. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037>.
Mega JL, Stitziel NO, Smith JG et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385(9984): 2264–2271. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(14)61730-X>.